Galmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study

TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramcholtm, an oral, once-daily, liver-targeted SCD1 modulator, for the treatment of non-alcoholic steatohepatitis (NASH), announces today that its management team will host a conference call and webcast to discuss top line, 52-week results from the global Phase 2b ARREST clinical trial that is investigating Aramchol for the treatment of non-alcoholic steatohepatitis (NASH).  Details of the call are below.

Conference Call and Webcast Information
Tuesday, June 12th @ 8:00am Eastern Time
Within the US: 1-800-239-9838
Outside the US: 1-323-794-2551
From Israel: 1809 212 883
Conference ID: 6065512
Webcast: http://public.viavid.com/index.php?id=130063  

Replays, Available through 06/26/18
Domestic: 1-844-512-2921
International: 1-412-317-6671
Replay PIN: 6065512

About Galmed Pharmaceuticals Ltd.:
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol^TM, a first-in-class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders.

Forward-Looking Statements:
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's ongoing Phase IIb ARREST Study, and planned Phase III trials for Aramcholtm, or whether Phase III trials will be conducted at all; completion and receiving favorable results of these Phase IIb ARREST Study and Phase III trials for Aramcholtm; regulatory action with respect to Aramcholtm by the FDA or the EMA; the commercial launch and future sales of Aramcholtm or any other future product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramcholtm in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramcholtm; Galmed's expectations regarding the commercial market for NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus; third-party payor reimbursement for Aramcholtm; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramcholtm by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramcholtm; the development and approval of the use of Aramcholtm for additional indications or in combination therapy; and Galmed's expectations regarding licensing, acquisitions and strategic operations. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on March 13, 2018, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Guy Nehemya, Vice President, Operations
Galmed Pharmaceuticals Ltd.
[email protected]

SOURCE Galmed Pharmaceuticals Ltd.